Global pneumococcal vaccines market  growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments.  Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

- This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global pneumococcal vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Vaccine Type
• • Pneumococcal Conjugate Vaccines (PCVs)
    • PCV13 (Prevnar 13/Prevenar 13)
    • PCV10 (Synflorix)
    • PCV7 (Prevnar/Prevenar)
  • Pneumococcal Polysaccharide Vaccines (PPVs)
    • PPSV23 (Pneumovax 23)
    • PPSV14 (Pneumo 14)
• By Target Population
• • Adults (≥ 65 years)
  • Children (< 5 years)
  • High-Risk Adults (18-64 years)
• By Route of Administration
• • Intramuscular
  • Subcutaneous
• By Distribution Channel
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Key Players Insights
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Sanofi
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte, Inc.
  • Astellas Pharma Inc.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd